What are the recommended monitoring and management steps for a patient with HIV on antiretroviral therapy, including criteria for regimen change and opportunistic infection prophylaxis?

HIV Management on Antiretroviral Therapy

For patients with HIV on ART, continue current therapy if virologically suppressed (HIV RNA <200 copies/mL), monitor viral load every 3-6 months once stable, and only switch regimens for confirmed virologic failure, significant toxicity, or to simplify therapy when fully suppressed. 1

Monitoring Strategy

Viral Load Monitoring

• Check HIV RNA 1 month after any regimen change 1
• Once suppressed (<50 copies/mL) for ≥1 year: monitor every 6 months 2
• If not yet at 1 year of suppression: monitor every 3 months 2
• Virologic failure is defined as HIV RNA >200 copies/mL 1

CD4 Count Monitoring

• Monitor CD4 counts alongside viral load
• CD4 recovery is a key marker for discontinuing opportunistic infection prophylaxis 3

When to Switch Therapy

For Virologic Suppression (Simplification)

You can switch from a 3-drug to 2-drug regimen if:

• Patient has achieved and maintained viral suppression
• Both agents in new regimen are fully active
• No prior resistance mutations to the new agents 1

Recommended 2-drug regimens:

• Dolutegravir/rilpivirine 1
• Dolutegravir/lamivudine 1
• Boosted PI + lamivudine 1
• Long-acting injectable cabotegravir/rilpivirine (every 4-8 weeks) 1, 4

Critical caveat: Never use monotherapy with boosted PIs or dolutegravir 1

For Virologic Failure

Immediate actions required:

1. Confirm the failure - repeat viral load to verify HIV RNA >200 copies/mL 1
2. Order resistance testing while patient is still on the failing regimen (or within 4 weeks of stopping) 1
3. Review complete ART history and all prior resistance tests 1
4. Assess adherence - distinguish true virologic failure from adherence issues 5

Switching algorithm based on failing regimen:

• NNRTI failure: Switch to dolutegravir + 2 NRTIs (with ≥1 active drug by genotype) 1
• InSTI failure: Switch to boosted PI + 2 NRTIs (with ≥1 active NRTI) 1
• Raltegravir/elvitegravir resistance: Use dolutegravir 50mg twice daily + ≥1 fully active agent 1
• PI failure: Rare to have resistance mutations; focus on adherence support or switch to improve tolerability 1
• 3-class resistance: Use drugs from new classes (fostemsavir or ibalizumab) + ≥1 additional active drug 1

Never add a single active agent to a failing regimen 1

For Toxicity/Intolerance

• Substitute alternative drugs of equal potency from the same class
• Can perform single-drug switches only if patient has maintained viral suppression (<50 copies/mL) 6

Special Populations Requiring Specific Management

HIV/HBV Co-infection

Must continue tenofovir (alafenamide or disoproxil fumarate) when switching regimens 1

• If tenofovir contraindicated, provide alternative HBV suppressive therapy
• Switching to lamivudine or emtricitabine alone without tenofovir will NOT maintain HBV suppression 1

Patients with NRTI Resistance

Do not switch from boosted PI to low genetic barrier drugs (NNRTIs or raltegravir) 1

Pregnancy

• Dolutegravir + tenofovir alafenamide/emtricitabine can be used during pregnancy 1
• Women already on effective regimens when becoming pregnant do not necessarily need to switch 1

Opportunistic Infection Prophylaxis

Discontinuation Criteria (with sustained CD4 recovery on ART)

Primary prophylaxis can be discontinued when: 3

• PCP prophylaxis: CD4 >200 cells/µL for ≥6 months
• Toxoplasmosis prophylaxis: CD4 >100-200 cells/µL for ≥6 months
• MAC prophylaxis: Similar CD4 thresholds apply

Key principle: Patients must have completed initial therapy and have no active symptoms of these infections 3

Critical Pitfalls to Avoid

1. Never review co-medications in isolation - check for drug-drug interactions, especially with tenofovir alafenamide dosing 1
2. Never switch regimens without reviewing complete resistance history - archived mutations matter 1
3. Never assume virologic failure without confirming adherence first - mental health disorders and substance use significantly impact adherence 5
4. Never use partially suppressive regimens - the goal is HIV RNA <50 copies/mL, not just "lower" 1
5. Never stop all ART if oral access is lost - coordinate with pharmacy for alternative formulations or temporary holds 7

Pre-Switch Checklist

Before any regimen change, systematically review: 1

• Complete ART history
• All prior resistance test results
• Current and past tolerability issues
• Co-medications and potential interactions
• Food requirements of new regimen
• Cost and insurance coverage
• Patient preference and adherence capacity